In a report released on November 28, Robert Hazlett from BTIG maintained a Buy rating on Rani Therapeutics Holdings (RANI – Research Report), with a price target of $24.00. The company’s shares closed yesterday at $8.11.
Hazlett covers the Healthcare sector, focusing on stocks such as Aravive, Verastem, and Paratek Pharmaceuticals. According to TipRanks, Hazlett has an average return of 1.6% and a 36.00% success rate on recommended stocks.
Rani Therapeutics Holdings has an analyst consensus of Strong Buy, with a price target consensus of $20.00.
See Insiders’ Hot Stocks on TipRanks >>
RANI market cap is currently $394M and has a P/E ratio of -6.73.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RANI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Read More on RANI:
